Chronic Spontaneous Urticaria
Advertisement
Around 70% of patients presenting to the emergency department for urticaria received diphenhydramine.
The Urticaria Activity Score is commonly utilized in chronic spontaneous urticaria clinical trials.
Acupuncture therapy as an adjunct to omalizumab was found to improve disease control and quality of life.
Patients with CSU who utilized a digital telehealth platform reported improved quality-of-life scores.
Urticaria raises the risk of ADHD, bipolar disorder, and schizophrenia.
Omalizumab is a safe and effective long-term treatment for CSU.
Nearly 50% of patients with chronic spontaneous urticaria are atopic, with atopy linked to increased risk of dermatographism,
A recent study demonstrated significant associations between acute urticaria and cardiovascular comorbidities.
Autoimmune mast cell activation test shows promise as a diagnostic tool for chronic spontaneous urticaria.
Omalizumab treatment in CSU patients leads to significant changes in T-cell subpopulations.
Patients with both asthma and chronic urticaria have more severe allergic responses.
Omalizumab effectively reduces symptoms in CSU patients, but a 300 mg dose is recommended.
A systematic review found that biologic omalizumab is cost-effective for treating H1 antihistamine–refractory CSU.
According to a recent study, serum zonulin levels had a significant correlation with the urticaria activity score
Eosinophil/neutrophil/platelet/basophil-to-lymphocyte ratios did not significantly change during 6 months of omalizumab.
Autologous serum skin test status positivity, comorbid allergic diseases are associated with early response to omalizumab.
Omalizumab updosing is commonly needed within the first 3 months of treatment for patients with severe CSU.
Stem cell factor expression was significantly elevated in both the lesional and nonlesional skin of patients with CSU.
Elevated serum orexin-A levels are associated with poorer sleep quality in patients with chronic spontaneous urticaria.
Low total immunoglobin E levels, high systemic inflammation response are predictors of poor response to omalizumab.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.